 |
Top 32 Neurology startups
Oct 11, 2024 | By Jason Kwon | 27 |
These startups develop new technologies to diagnose and treat neurological conditions, such as transcranial magnetic stimulation, brain-computer interfaces, deep brain stimulation, artificial intelligence for diagnostic imaging, personalized drug therapy.
1
Country: USA | Funding: $612M
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
2
Country: USA | Funding: $544.8M
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.
3
Country: France | Funding: $356.6M
Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
4
Country: USA | Funding: $307.3M
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
5
Country: USA | Funding: $269.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
6
Country: USA | Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
7
Country: USA | Funding: $257.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
8
Country: UK | Funding: $239.7M
PepGen is empowering nucleic acid therapeutics to go the distance and building neuromuscular and neurologic pipeline.
PepGen is empowering nucleic acid therapeutics to go the distance and building neuromuscular and neurologic pipeline.
9
Country: USA | Funding: $220.5M
Ceribell is focused on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective
Ceribell is focused on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective
10
Country: USA | Funding: $181.2M
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
